Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Design Therapeutics, Inc. DSGN
$6.69
+$0.33 (4.95%)
На 18:04, 12 мая 2023
+308.52%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
424627104.00000000
-
week52high
26.30
-
week52low
4.90
-
Revenue
0
-
P/E TTM
-7
-
Beta
1.17863200
-
EPS
-1.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Outperform | Outperform | 09 авг 2022 г. |
| Wedbush | Outperform | 10 июн 2022 г. | |
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 мая 2022 г. |
| RBC Capital | Outperform | 02 мая 2022 г. | |
| SVB Leerink | Outperform | Outperform | 09 дек 2022 г. |
| RBC Capital | Outperform | Outperform | 08 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Siffert Joao MD | A | 415000 | 415000 | 01 февр 2023 г. |
| Shah Pratik | A | 415000 | 415000 | 01 февр 2023 г. |
| Jeffries Sean | A | 140000 | 140000 | 01 февр 2023 г. |
| Burgess Julie | A | 75000 | 75000 | 01 февр 2023 г. |
| Siffert Joao MD | A | 132619 | 6300 | 20 дек 2022 г. |
| George Simeon | A | 6526476 | 40000 | 20 дек 2022 г. |
| SR One Capital Fund I Aggregator LP | A | 6526476 | 40000 | 20 дек 2022 г. |
| Siffert Joao MD | A | 126319 | 1150 | 19 дек 2022 г. |
| George Simeon | A | 6486476 | 360000 | 19 дек 2022 г. |
| SR One Capital Fund I Aggregator LP | A | 6486476 | 360000 | 19 дек 2022 г. |
Новостная лента
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
GlobeNewsWire
17 окт 2022 г. в 16:05
Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022 Company On-track to Report Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 in the Fourth Quarter of 2022
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
GlobeNewsWire
22 сент 2022 г. в 06:30
CARLSBAD, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the 2022 Jefferies Cell and Genetic Medicine Summit on Thursday, September 29, 2022, at 10:00 a.m. ET in NYC.
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
GlobeNewsWire
01 июн 2022 г. в 06:30
CARLSBAD, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that João Siffert, M.D., president and chief executive officer, will present at the 2022 Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 8:30 a.m. ET in New York City.